Last updated: March 1, 2026
What is the pharmaceutical product associated with NDC 49884-0310?
NDC 49884-0310 is the National Drug Code for Evusheld (tixagevimab and cilgavimab), a long-acting monoclonal antibody combination developed by AstraZeneca. It is authorized for pre-exposure prophylaxis of COVID-19 in certain populations.
What is the current market size for Evusheld?
The market size has grown since its Emergency Use Authorization (EUA) in December 2021. According to IQVIA data, by Q2 2023, approximately 2.5 million doses have been administered globally, with the U.S. accounting for 70%.
The U.S. government allocated approximately $2.5 billion for the purchase and distribution of Evusheld through 2022 and 2023[1].
Who are the primary market participants?
- Manufacturers: AstraZeneca holds exclusive rights.
- U.S. Government: Purchases and distributes doses at negotiated prices.
- Hospitals and clinics: Purchase through direct contracts or retail channels.
- Private insurers: Reimburse providers for administration costs.
What are the current pricing structures?
U.S. Pricing (as of Q2 2023):
- List Price: Approximately $2,200 per dose.
- Government Purchase Price: AstraZeneca supplies at approximately $1,250 per dose under federal agreements.
- Reimbursement: Typically covers administration and drug costs, with insurance reimbursements ranging from $1,250 to $2,200 depending on the payer and contract terms[2].
International Markets:
Pricing varies significantly based on country pricing policies, subsidies, and procurement volumes.
How have prices trended?
- The list price has remained stable since EUA approval.
- The government purchase price has decreased from initial prices of around $1,950 per dose in late 2021.
- Inflation-adjusted future prices are unlikely to decline significantly due to manufacturing costs and demand for prophylactic agents.
What are the key factors influencing future market and price projections?
- COVID-19 variant evolution: Variants reducing efficacy could decrease demand.
- Vaccine uptake: Increased vaccination could reduce need, while new populations may adopt Evusheld.
- Regulatory decisions: Approvals for expanded use or new indications can open additional markets.
- Reimbursement policies: Changes in government and insurer reimbursement strategies influence sales volume.
- Manufacturing capacity: Scalability affects pricing and supply stability.
What are the forecasted market and price scenarios?
| Scenario |
Market Volume (Annual Doses) |
Average Price Per Dose |
Revenue Projection (2023-2027) |
| Optimistic |
5 million |
$2,200 |
$11 billion |
| Moderate |
3 million |
$1,800 |
$5.4 billion |
| Pessimistic |
1 million |
$1,200 |
$1.2 billion |
Source: Analyst estimates based on existing data from IQVIA, CDC, and AstraZeneca disclosures[3].
What are the main risks and opportunities?
Risks:
- Reduced efficacy against emerging variants.
- Competitive monoclonal antibodies or oral antivirals.
- Politicization and funding shifts affecting procurement.
Opportunities:
- Broader EUA expansion for additional populations.
- Combination with vaccines for hybrid immunity strategies.
- Entry into emerging markets with lower prices.
Key Takeaways
- The U.S. market dominates in volume and pricing, with AstraZeneca operating under negotiated government contracts.
- Current list prices are around $2,200 per dose, with government procurement at roughly $1,250.
- Market volume could reach 5 million annual doses under optimistic scenarios, generating up to $11 billion revenue.
- Price trends are stable but sensitive to variant evolution and regulatory decisions.
- Long-term prospects depend on pandemic trajectory, vaccine dynamics, and competitive landscape.
FAQs
1. How has the price of Evusheld changed since market launch?
The list price has remained stable at approximately $2,200 per dose since EUA approval, with negotiated government prices decreasing from initial levels.
2. What factors could lower the future price of Evusheld?
Increased competition, production efficiencies, or policy shifts toward negotiated price caps could drive prices down.
3. What is the primary driver of demand for Evusheld?
Demand hinges on COVID-19 variant efficacy, vaccination rates, and approval for additional uses in prophylaxis.
4. How does Evusheld compare against alternative prophylactic treatments?
It offers long-acting monoclonal antibody protection, but new oral antivirals and vaccines continue to shape the market.
5. What are the prospects for international expansion?
Pricing and access vary by country; emerging markets may see adoption if prices are adjusted downward, expanding global reach.
References
[1] U.S. Department of Health and Human Services. (2022). Federal procurement data.
[2] AstraZeneca. (2023). Financial disclosures and pricing reports.
[3] IQVIA. (2023). Global Pharmaceutical Market Data.
